GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study

GSK's dostarlimab (Jemperli) met primary endpoints in a Phase 2 trial for dMMR rectal cancer, showing sustained complete responses at 12 months and enabling patients to avoid surgery, chemotherapy, and radiation. The company plans FDA filing with expedited review under the National Priority Review Voucher programme.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.